SCH772984

For research use only.

Catalog No.S7101

388 publications

SCH772984 Chemical Structure

CAS No. 942183-80-4

SCH772984 is a novel, specific inhibitor of ERK1/2 with IC50 values of 4 nM and 1 nM in cell-free assay, respectively, And show robust efficacy in RAS- or BRAF-mutant cancer cells.

Selleck's SCH772984 has been cited by 388 publications

Purity & Quality Control

Choose Selective ERK Inhibitors

Biological Activity

Description SCH772984 is a novel, specific inhibitor of ERK1/2 with IC50 values of 4 nM and 1 nM in cell-free assay, respectively, And show robust efficacy in RAS- or BRAF-mutant cancer cells.
Features Does not directly inhibit MEK1, MEK2, BRAF, or CRAF enzyme activity.
Targets
ERK2 [1]
(Cell-free assay)
ERK1 [1]
(Cell-free assay)
1 nM 4 nM
In vitro

SCH772984 is a novel, selective and ATP competitive inhibitor of ERK1/2. SCH772984 inhibits phosphorylation of the ERK substrate p90 ribosomal S6 kinase (T359/S363 phospho-RSK) in a dose-dependent manner. SCH772984 also inhibits phosphorylation of residues in the activation loop of ERK itself. SCH772984 demonstrates EC50 values <500 nM in approximately 88% and 49% of BRAF-mutant or RAS-mutant tumor lines, respectively. Importantly, SCH772984 effectively inhibited MAPK signaling and cell proliferation in tumor cells resistant to concurrent treatment with BRAF and MEK inhibitors. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
2P-ERK2 NEj1N3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jjbmlEPTB;MD6yOEBvVQ>? MkWyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|NUC5N|EoRjJ3M{WwPVMyRC:jPh?=
WM-266-4 NGHLeYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3YT2JKSzVyPUKwJI5O MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
UACC-62 Ml3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLnTWM2OD1|MDDuUS=> M3uyPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
Colo-205 NYjHVndJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnsWnhwUUN3ME2zOkBvVQ>? MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
SK-Mel-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\RbY9KSzVyPUO3JI5O M4[wSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
WiDr MkC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPwO2lKSzVyPUO5JI5O NVnwcJAxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
M14 M2LCW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXr5c3I1UUN3ME20O{BvVQ>? M1PkZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
HT-29 NWD5c3FzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTVyIH7N NGSzbWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
8505C NU\3ZXFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHr4ZmpKSzVyPUWwJI5O NILsS5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
HT-144 M13RT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HWOmlEPTB;NkCgcm0> NUXJPIlRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
SK-Mel-5 MojWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjldI9KSzVyPU[2JI5O M3nNS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
A375-SM NYrsPFlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzaTWM2OD15NTDuUS=> NF3mfmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
SK-Mel-28 NYrFcWw5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXjTWM2OD16NTDuUS=> MkHZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
LOX MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTFyMDDuUS=> M4K3XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
SK-Mel-3 M2flRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3YPVVKSzVyPUGxPEBvVQ>? NI\nTZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
K1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHizNGhKSzVyPUGzNEBvVQ>? MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
Hs-695T MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDIcIhKSzVyPUG2OUBvVQ>? NVH0OWE1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
BHT-101 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{j6SGlEPTB;M{CwJI5O M{XVZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
RPMI-7951 MmeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrNbnlKSzVyPUO0OEBvVQ>? MojqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
A2058 NXm5[YFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTN4MDDuUS=> MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
SK-Hep-1 NVTkdmJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjLVYk2UUN3ME2xOFIzKG6P MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
A673 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIL0eYFKSzVyPUOwNFEhdk1? Mn3SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
DBTRG-05MG NXWxOWFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Pn[2lEPTB;M{CwNUBvVQ>? MnvaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
SW-626 NVXxUFB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPJTWM2OD1|MzDuUS=> MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
LoVo NHLmTlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGL6dYJKSzVyPUS3JI5O NXHnVFF[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
MiaPaCa NVvoV5NPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVK0dIVQUUN3ME21N{BvVQ>? MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
SW-620 NFLpfG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVv2VIhHUUN3ME2xNFQhdk1? NF:2WnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
CAPAN-1 Mn;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3ZTWM2OD1zMESgcm0> M3\RdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
SW-527 M4DaZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEK2SIdKSzVyPUGyNUBvVQ>? MkP6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
HCT-116 M3XWZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DHO2lEPTB;MUK4JI5O M4q4cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
SW-480 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvzTINKSzVyPUG2OUBvVQ>? M4HWTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
HPAC NGD0PJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLsPGJRUUN3ME2xO|Ahdk1? MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
OVCAR-5 M4jiWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTJyODDuUS=> NHXVb5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
AsPc-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWD1Uo1pUUN3ME2yO|Ahdk1? M2TEVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
A549 NHzG[nFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTObG5FUUN3ME2zNlYhdk1? NXnrS5VTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
SNU-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nybGlEPTB;M{W0JI5O M3LCSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
HOP62 M{DIUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPYTWM2OD14N{[gcm0> NIrX[3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
H23 M{jZOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXkTWM2OD1zMECwJI5O NV3B[np7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
MB-231 NX3SUXMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHIWXVKSzVyPUGwNFAhdk1? NGfTe|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
SU.86.86 NH3NcpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHCNWpJUUN3ME2xNFAyKG6P NYjJZ5NvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
CFPAC-1 NY\3R3hsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTSTWM2OD1zMECxJI5O MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
A427 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn[0TWM2OD1zNEOzJI5O M1\yNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
MDAH-2774 M2O5e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTJ4NUegcm0> M1WwOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
NCI-H157 M3rFUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFu4U2FKSzVyPUOwNFAhdk1? NHL1PHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
HTB-177 NFTzUGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7rco9KSzVyPUOwNFAhdk1? NYTTNHJwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
UM-UC-3 M1zZbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3S1SWlEPTB;M{CwNUBvVQ>? M4n3dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
HCT-8 M2O0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\YUWlEPTB;M{CwNUBvVQ>? NGXPSXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
Panc-1 NFHqcZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDEcVFKSzVyPUOwNFEhdk1? NWf4VoRzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
DLD-1 MoHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rSO2lEPTB;M{CwNUBvVQ>? M{fpOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
HCT-15 NIfMZpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTNyMEGgcm0> M{DtXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
HL-60 M4n6Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\OTWM2OD1|MDDuUS=> M{XGb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
SK-Mel-2 NH\mSZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTN2IH7N NUjJU3JIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
RD NVryeGhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTF{MzDuUS=> MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
HT-1197 NXvJOHZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HY[2lEPTB;M{G2JI5O M1PkSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
Molt-3 NFizXZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXkW49KSzVyPU[wNEBvVQ>? NE\VWXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
PA-1 NXXQVFlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlqzTWM2OD1zMECxJI5O MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
Molt-4 MnP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTNyMEGgcm0> MnzSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
NCI-H292 NXHSTVh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nzd2lEPTB;OUCgcm0> M{\XRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
A2780 NIfkVnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTF2MzDuUS=> MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
IGROV-1 NV7zS49[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDGU25{UUN3ME2xOFYhdk1? M{\iOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
SK-N-SH MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LNVWlEPTB;MUWwJI5O MmnvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
N-87 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrsOJlKSzVyPUOwO{BvVQ>? NWPyW2RHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
H322 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnkeHlKSzVyPUOyOUBvVQ>? NYm5TFh1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
H716 M{Gyc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjDTG5KSzVyPUOzOEBvVQ>? NYTpPVdFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
TT NWm0TYtmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXu4d4NYUUN3ME20NFYhdk1? NFzHOVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
Caki-1 M{nD[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLmTWM2OD12NUCgcm0> M3vmdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
5637 NHLBT5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\Ob296UUN3ME22NVAhdk1? M1:1UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
MB-453 MmP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnCZmxKSzVyPU[3NkBvVQ>? M13sclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
RT-4 NVfO[nd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;HSGlEPTB;OEGwJI5O MmLyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
HOP92 MlrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLnNVFKUUN3ME24NlAhdk1? NIPsW4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
KG-1 MnSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTlyMDDuUS=> MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
Hs-294T MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlm0TWM2OD17NEWgcm0> MkC1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
SF-539 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\YTWM2OD1zMECwJI5O MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
U-251 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3f4R2lEPTB;MUCwNEBvVQ>? MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
MB-468 NHvuN2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfJTWM2OD1zMECwJI5O MoPyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
HS746T NFHRcIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnL6TWM2OD1zMECwJI5O M1rpcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
SCABER NWLZdIEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTFyMECgcm0> Mmj0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
MCF-7 NUjiW2t[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvXTWM2OD1zMECxJI5O NGjDZWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
CHL-1 MlnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfkWnFKSzVyPUG0OlAhdk1? MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
U87MG MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTJyMECgcm0> MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
SJCRH30 M4HUW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTJyMEKgcm0> NH:yOFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
ES-2 NVTIeW86T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXKWYtZUUN3ME2yOlU6KG6P MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
HT-1376 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXWTWM2OD1{OECwJI5O NWfmW49RRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
A172 MlX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mof2TWM2OD1|MECwJI5O NXXE[XFRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
769P MmPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnqbpVKSzVyPUOwNFAhdk1? M1exRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
NCI-H520 NFf4VoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vudmlEPTB;M{CwNEBvVQ>? M2TPc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
DU145 MoPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\5XFZKSzVyPUOwNFAhdk1? NUDrRWxYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
K562 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUixXm1QUUN3ME2zNFAxKG6P NX\WeHlERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
U-937 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7DTWM2OD1|MECwJI5O M4\PeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
A204 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI[xeIdKSzVyPUOwNFEhdk1? NYfod2hHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
DAOY MoT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHuZ2l6UUN3ME2zNFAyKG6P M3:5OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
SF-268 M2D4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mom2TWM2OD1|MECxJI5O NFTvcmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
SF-295 M{TFfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTNyMEGgcm0> MmLLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
SNB-19 NYW4ell[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1[2XmlEPTB;M{CwNUBvVQ>? NYnJ[XdGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
SNB-75 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkmzTWM2OD1|MECxJI5O NX21OYFnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
U373-MG NILK[nlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTNyMEGgcm0> MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
786-O NInI[5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTNyMEGgcm0> MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
A498 NHrBdWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTNyMEGgcm0> M{ns[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
ACHN MnPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTNyMEGgcm0> MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
EKVX MoPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvFTWM2OD1|MECxJI5O NWLwbJZERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
H226 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIKwR2pKSzVyPUOwNFEhdk1? NEXnTGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
H522 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HkOWlEPTB;M{CwNUBvVQ>? NV\2OYdkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
HeLa MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTNyMEGgcm0> NH\4dlA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
SK-OV-3 M2\qPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHkcXNKSzVyPUOwNFEhdk1? NFTCSpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
Ln Cap NH;HZopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPRTWM2OD1|MECxJI5O NFH2Rmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
PC3 NH;XV29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37Ub2lEPTB;M{CwNUBvVQ>? NVPUeGo3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
SNU-16 NX3m[llvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTNyMEGgcm0> MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
FTC-133 MojRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4G4PGlEPTB;M{CwNUBvVQ>? MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
Ro82-W-1 MmrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4n5S2lEPTB;M{CwNUBvVQ>? Ml3GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
Daudi NFricJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLoTWM2OD1|MECxJI5O MlO4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
Jijoye M4\GbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLXTWM2OD1|MECxJI5O MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
Jurkat Mn\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{f5eGlEPTB;M{CwNUBvVQ>? Mn\5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
J-82 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTNyMEGgcm0> Mn;5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
TCC-SUP NF7VRoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTNyMEGgcm0> NHrQfHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
BT-474 NWjqNlEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7NTWM2OD1|MECxJI5O MnW0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
ZR-75-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE[yOZpKSzVyPUOwNFEhdk1? NFW4SIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
A375 MlPySpVv[3Srb36gZZN{[Xl? M4C0c|IhcHK| NFjjPWRKdmirYnn0bY9vKG:oIFXST|IhcW5iaIXtZY4hSTN5NTDj[YxteyCqYYLic5JqdmdiQj3SRWYhXjZyMFWgcZV1[W62IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKHCqb4PwbI8uTVKNMjDs[ZZmdCCjZoTldkAzKGi{czDifUBE\Wyub33pZ5MhSXK{YYnTZ4FvXE1iVmTJJIlu[WerbnegZY5idHm|aYOsJGlEPTBiPTCwMlAxPCEQvF2u MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl5N{m4NUc,OjV7N{e5PFE9N2F-
A375 NWjiWGJ2TnWwY4Tpc44h[XO|YYm= MYXJcohq[mm2aX;uJI9nKEWUS{KgbY4hcHWvYX6gRVM4PSClZXzsd{Bp[XKkb4LpcochSlKDRjDWOlAxTSCvdYThcpQh[XO|ZYPz[YQh[XNiZHXjdoVie2ViaX6gdIhwe3Cqb4L5cIF1\WRiRWLLNkBt\X[nbIOsJGlEPTBiPTCwMlAxPCEQvF2u MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDN5NkOwOkc,Ojh|N{[zNFY9N2F-
COLO205 NHLl[4dCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NFm3VI01KGSjeYO= NVPuWFQ5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDDU2xQOjB3IHPlcIx{KGijcnLvdolv\yCEUlHGJHY3ODCHL1SgcZV1[W62IH3lZZN2emWmIHHmeIVzKDRiZHH5d{whUUN3MDC9JFAvODF4IN88UU4> NGL4RmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MECzOFYyPSd-M{CwN|Q3OTV:L3G+
A375 MnntSpVv[3Srb36gZZN{[Xl? MnixNkBpenN? NFPGfFBKdmirYnn0bY9vKG:oIFXST|EwOiCrbjDoeY1idiCDM{e1JINmdGy|IHjhdoJwemmwZzDCMXJCTiCYNkCwSUBufXSjboSgZZN{\XO|ZXSgZZMh\GWlcnXhd4UhcW5icHjvd5Bpdy2UU1ugcIV3\WxiYX\0[ZIhOiCqcoOgZpkhS2WubH;tbYN{KEG{cnH5V4NidlSPIG\UTUBqdWGpaX7nJIFv[Wy7c3nzMEBKSzVyIE2gNE4xOiEQvF2u M{nLXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUe3PVgyLz5{NUm3O|k5OTxxYU6=
A375 NVTle5RZTnWwY4Tpc44h[XO|YYm= NF;VbYczKGi{cx?= NUHIOWQzUW6qaXLpeIlwdiCxZjDFVmsyNzJiaX6gbJVu[W5iQUO3OUBk\WyuczDoZZJjd3KrbnegRk1TSUZiVk[wNGUhdXW2YX70JIF{e2W|c3XkJIF{KGSnY4LlZZNmKGmwIIDoc5NxcG9vUmPLJIxmfmWuIHHmeIVzKDJiaILzJIJ6KEOnbHzvcYlkeyCDcoLhfXNk[W6WTTDWWGkhcW2jZ3nu[{BidmGueYPpd{whUUN3MDC9JFAvODJizszNMi=> MlzJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7N{e5PFEoRjJ3OUe3PVgyRC:jPh?=
A375 M3XMZWZ2dmO2aX;uJIF{e2G7 MX\Jcohq[mm2aX;uJI9nKEWUS{KgbY4hcHWvYX6gRVM4PSClZXzsd{Bp[XKkb4LpcochSlKDRjDWOlAxTSCvdYThcpQh[XO|ZYPz[YQh[XNiZHXjdoVie2ViaX6gdIhwe3Cqb4L5cIF1\WRiUmPLJIxmfmWuczygTWM2OCB;IECuNFIh|ryPLh?= M3\heFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{e2N|A3Lz5{OEO3OlMxPjxxYU6=
HT-29 MW\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NVG2eo5wPCCmYYnz NY[5Z4RjSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{Bp[XKkb4LpcochSlKDRjDWOlAxTS:GIH31eIFvfCCvZXHzeZJm\CCjZoTldkA1KGSjeYOsJGlEPTBiPTCwMlA2QSEQvF2u M3j0eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEO0OlE2Lz5|MECzOFYyPTxxYU6=
HT-29 MWHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? Mn21RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKVD2yPUBk\WyuczDoZZJjd3KrbnegRnJCTi:NUlHTJI12fGGwdDygTWM2OCB;IECuNFU6KM7:TT6= NEDzOZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe0PFA2OSd-Mkm3OFgxPTF:L3G+
A375 MUTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NFK1dlA4OiCqcoO= NUDWW2pbSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBN|c2KGOnbHzzJIhiemKxcnnu[{BDNVKDRjDWOlAxTSCvdYThcpQh[W[2ZYKgO|IhcHK|IHL5JGNmdGyxbXnjd{BCenKjeWPjZY5VVSCYVFmgbY1i\2mwZzDhcoFtgXOrczygTWM2OCB;IECuNFch|ryPLh?= NW[1PVVwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5O|c6QDFpPkK1PVc4QThzPD;hQi=>
HT-29 M{nacGFxd3C2b4Ppd{Bie3OjeR?= MkLBTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCKVD2yPUBk\WyuczDoZZJjd3KrbnegRnJCTi:NUlHTJI12fGGwdDDifUBk[XOyYYPlJIFkfGm4YYTpc44h[XO|YYmsJGlEPTBiPTCwMlA6PiEQvF2u NFfJS|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe0PFA2OSd-Mkm3OFgxPTF:L3G+

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
cyclin B1 / cyclin D1 / p21; 

PubMed: 26725216     


Cells treated as above were collected for western blot for total cyclin B1, cyclin D1 and p21, and of phosphorylated, inactivated RB (S807/811; pRB). Western blot for pERK was done to verify SCH772984 inhibition; β-actin was the loading control.

pRSK / pERK / pAKT / pMEK; 

PubMed: 26725216     


Cells were treated for 4 or 24 hr with DMSO vehicle or SCH772984, then evaluated by western blot with phospho-specific antibodies for RSK (T395/S363; pRSK), MEK1/2 (S217/221; pMEK), AKT (S473; pAKT), and ERK (T202/Y204; pERK). Total RSK, ERK, AKT, MEK and β-actin were also analyzed. Data are representative of three independent experiments.

DUSP1 / DUSP4 / DUSP6; 

PubMed: 26725216     


Cells were treated for 4 or 24 hr with DMSO vehicle or SCH772984 for 72 hr and evaluated by western blot for DUSP1, DUSP4, DUSP6 and β-actin.

pCRAF(S338, S289, S296, S301); 

PubMed: 26725216     


Cells were treated for 4 or 24 hr with DMSO vehicle or SCH772984 for 72 hr and evaluated by western blot for pCRAF (S338), pCRAF (S289/296/301), total CRAF and β-actin.

Aurora B / ETS1 / ETS2; 

PubMed: 26725216     


Cells were treated with vehicle or SCH772984 for 7 days, then immunoblotted for Aurora B, MYC, ETS1 or ETS2, and β-actin. Data are representative of three independent experiments.

26725216
Growth inhibition assay
Cell viability; 

PubMed: 30118499     


NCI-H747, SW837, SW480, and SW620 cells were treated with the ERK inhibitor SCH772984 at indicated concentrations for 72 hours. Dimethyl sulfoxide (DMSO) (0.01%) was used as the control treatment. Each data point represents the mean of five replicates; error bars indicate one SD.

30118499
Immunofluorescence
TOMM20; 

PubMed: 30833752     


Mitochondrial morphologies of PDAC cells treated with SCH772984 (ERKi, 1 µM) for 24 h. Green, Anti-TOMM20; blue, DAPI; scale bar, 20 μm.

pERK1/2; 

PubMed: 30213106     


After treatment with 10 µM of the ERIK1/2 inhibitors, the expression of p-ERK1/2 protein in HeLa cells was detected using immunofluorescence (400×), bar = 50 μm.

30833752 30213106
In vivo SCH772984 induces tumor regressions in xenograft models at tolerated doses. SCH772984 effectively inhibites MAPK signaling and cell proliferation in BRAF or MEK inhibitor resistant models. [1]

Protocol

Kinase Assay:

[1]

- Collapse

ERK2 IMAP enzymatic assay:

SCH772984 is tested in 8 point dilution curves in duplicate against purified ERK2 or ERK1. The enzyme is added to the reaction plate. and incubated with the compound before adding a solution of substrate peptide and ATP. 14μl of diluted enzyme (0.3ng active ERK2 per reaction) is added to each well of a 384-well plate. The plates are gently shaken to mix the reagents and incubated for 45 minutes at room temperature. The reaction is stopped with 60μl of IMAP Binding Solution (1:2200 dilutions of IMAP beads in 1X Binding Buffer). The plates are incubated at room temperature for an additional 0.5 hours to allow complete binding of phosphopeptides to the IMAP beads. Plates are read on the LJL Analyst.
Cell Research:

[1]

- Collapse
  • Cell lines: BRAF-mutant or RAS-mutant tumor lines
  • Concentrations: ~10 μM
  • Incubation Time: 5 days
  • Method:

    Cell proliferation experiments are performed in a 96-well format (six replicates), and cells are plated at 4,000/well density. At 24 h after cell seeding, cells are treated with DMSO or 9 point IC50 dilution (0.001-10 μM) at 1% DMSO final for all concentrations. Viability is assayed on 5 days after dosing using ViaLight luminescence kit following the manufacturer’s recommendations. For cell line panel viability assay, cells are treated with SCH772984 for 4 days and assayed by CellTiterGlo luminescent cell viability assay.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: Nude mice
  • Dosages: 12.5 mg/kg, 25 mg/kg, 50 mg/kg
  • Administration: i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 14 mg/mL warmed (23.82 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
0.6mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 587.67
Formula

C33H33N9O2

CAS No. 942183-80-4
Storage powder
in solvent
Synonyms N/A
Smiles C1CN(CC1C(=O)NC2=CC3=C(C=C2)NN=C3C4=CC=NC=C4)CC(=O)N5CCN(CC5)C6=CC=C(C=C6)C7=NC=CC=N7

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to inhibit Erk1/2 by treating the mice with the inhibitor. by what kind of administration way and at what concentration could it be done?

  • Answer:

    SCH772984 can be administrated by I.P. The dosages can be used as: 12.5 mg/kg, 25 mg/kg, 50 mg/kg. For more detail information please find the paper below: http://cancerdiscovery.aacrjournals.org/content/3/7/742.full

ERK Signaling Pathway Map

Tags: buy SCH772984 | SCH772984 supplier | purchase SCH772984 | SCH772984 cost | SCH772984 manufacturer | order SCH772984 | SCH772984 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID